Literature DB >> 20106619

[Multiple sclerosis in Haute-Garonne: an important underestimation of case numbers].

C Sagnes-Raffy1, P-A Gourraud, V Hannon, R Bourrel, M-A Laffontan, M-C Gaulene, F Viala, M Clanet.   

Abstract

INTRODUCTION: In France, the prevalence of multiple sclerosis is estimated between 65 and 125 patients per 100,000 inhabitants with a South-West towards North-East gradient. Nevertheless, the epidemiology of multiple sclerosis remains still imperfectly known, the recent studies being realized, either in a region of France, or from a single data source and thus suscepted not to be exhaustive.
OBJECTIVE: Assessing the prevalence of the multiple sclerosis in 2005 in Haute-Garonne by matching several data sources completed by a capture-recapture method; estimating the exhaustivity of each of the sources.
METHODS: The data sources were hospital data (DRG for the hospitalization, data of consultation), data of public health insurance system (main health insurance, agricultural health insurance, social welfare for self employed), and data from the MIPSEP network. The linkage was based on name, maiden name, first name, date of birth and sex and allowed a first estimation of the number of cases. Models of loglinear regression allowed estimating the total number of case and the sensitivity of each source.
RESULTS: The total number of cases obtained by matching several sources of information amounted to 1549. The use of several data sources increased by 25.6 % the maximum number of patients identified with a single source of information (national health insurance, any insurance). According to the model used, the method of capture-recapture estimated the number of cases up to 1722. Therefore, this study estimated a prevalence of multiple sclerosis between 110 and 149 cases per 100,000 inhabitants in Haute-Garonne.
CONCLUSION: The prevalence of the multiple sclerosis is largely underestimated in Haute-Garonne and questions the magnitude over the so-called gradient. Matching several sources of information is indispensable to improve collection of the total number of cases.

Entities:  

Mesh:

Year:  2010        PMID: 20106619     DOI: 10.1016/j.respe.2009.08.012

Source DB:  PubMed          Journal:  Rev Epidemiol Sante Publique        ISSN: 0398-7620            Impact factor:   1.019


  5 in total

1.  Incidence of multiple sclerosis in Northern Lisbon, Portugal: 1998-2007.

Authors:  Joao de Sá; Enrique Alcalde-Cabero; Javier Almazán-Isla; Fernando García-López; Jesús de Pedro-Cuesta
Journal:  BMC Neurol       Date:  2014-12-21       Impact factor: 2.474

Review 2.  Incidence and prevalence of multiple sclerosis in Europe: a systematic review.

Authors:  Elaine Kingwell; James J Marriott; Nathalie Jetté; Tamara Pringsheim; Naila Makhani; Sarah A Morrow; John D Fisk; Charity Evans; Sarah Gabrielle Béland; Sophie Kulaga; Jonathan Dykeman; Christina Wolfson; Marcus W Koch; Ruth Ann Marrie
Journal:  BMC Neurol       Date:  2013-09-26       Impact factor: 2.474

3.  Geographical Heterogeneity of Multiple Sclerosis Prevalence in France.

Authors:  Diane Pivot; Marc Debouverie; Michel Grzebyk; David Brassat; Michel Clanet; Pierre Clavelou; Christian Confavreux; Gilles Edan; Emmanuelle Leray; Thibault Moreau; Sandra Vukusic; Guy Hédelin; Francis Guillemin
Journal:  PLoS One       Date:  2016-12-09       Impact factor: 3.240

4.  Geographic variations of multiple sclerosis prevalence in France: The latitude gradient is not uniform depending on the socioeconomic status of the studied population.

Authors:  Philippe Ha-Vinh; Stève Nauleau; Marine Clementz; Pierre Régnard; Laurent Sauze; Henri Clavaud
Journal:  Mult Scler J Exp Transl Clin       Date:  2016-02-11

5.  Prevalence and mortality of patients with multiple sclerosis in France in 2012: a study based on French health insurance data.

Authors:  Stéphanie Foulon; Géric Maura; Marie Dalichampt; François Alla; Marc Debouverie; Thibault Moreau; Alain Weill
Journal:  J Neurol       Date:  2017-05-17       Impact factor: 4.849

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.